Literature DB >> 16041276

Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange.

Bekir Tanriover1, Peale Chuang, Bernard Fishbach, J Harold Helderman, Tarik Kizilisik, William Nylander, David Shaffer, Anthony J Langone.   

Abstract

Serum sickness is an immune-complex mediated illness that frequently occurs in patients after polyclonal antibody therapy (ATGAM or thymoglobulin). Serum sickness presents with significant morbidity but is self-limited and resolves with prolonged steroid therapy. We present five renal transplant patients who developed serum sickness after polyclonal antibody treatment with severe symptoms that persisted after being started on systemic steroids. These patients underwent one or two courses of therapeutic plasma exchange (TPE) with subsequent complete resolution of their symptoms. Renal transplant recipients with serum sickness after polyclonal antibody therapy may benefit from TPE by accelerating their time to recovery and thereby reducing overall morbidity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041276     DOI: 10.1097/01.tp.0000165093.13046.b3

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Ruling out false-positive urinary Legionella pneumophila serogroup 1 and Streptococcus pneumoniae antigen test results by heating urine.

Authors:  C Pontoizeau; L Dangers; V Jarlier; C E Luyt; E Guiller; M H Fievet; M Lecsö-Bornet; A Aubry; F Brossier
Journal:  J Clin Microbiol       Date:  2014-09-24       Impact factor: 5.948

2.  Hypersensitivity to rabbit antithymocyte globulin in an islet transplant recipient: a case report.

Authors:  S A Soleimanpour; D R Sekiguchi; D F LaRosa; E T Luning Prak; A Naji; M R Rickels
Journal:  Transplant Proc       Date:  2011-11       Impact factor: 1.066

3.  Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure.

Authors:  Raghavender Boothpur; Karen L Hardinger; Rebecca M Skelton; Brunilda Lluka; Matthew J Koch; Brent W Miller; Niraj M Desai; Daniel C Brennan
Journal:  Am J Kidney Dis       Date:  2009-07-23       Impact factor: 8.860

4.  Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.

Authors:  Bekir Tanriover; Vishal Jaikaransingh; Malcolm P MacConmara; Justin R Parekh; Swee-Ling Levea; Venkatesh K Ariyamuthu; Song Zhang; Ang Gao; Mehmet U S Ayvaci; Burhaneddin Sandikci; Nilum Rajora; Vaqar Ahmed; Christopher Y Lu; Sumit Mohan; Miguel A Vazquez
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-30       Impact factor: 8.237

5.  Is thymoglobulin or rituximab the cause of this serum sickness? A case report of serum sickness dilemma and literature review.

Authors:  Amarpreet Sandhu; Antonia Harford; Pooja Singh; Eduardo Alas
Journal:  Case Rep Med       Date:  2012-09-27

6.  Serum sickness following rabbit anti-thymocyte globulin for acute vascular renal allograft rejection.

Authors:  Jessie Teng; Xing Ning Hoo; Sven-Jean Tan; Karen Dwyer
Journal:  Clin Kidney J       Date:  2012-06-13

7.  Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation.

Authors:  Namita Singh; Ana P Rossi; Marizela Savic; Ronald J Rubocki; Mark G Parker; John P Vella
Journal:  Transplant Direct       Date:  2018-02-02

8.  Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection.

Authors:  Marieke van der Zwan; Marian C Clahsen-Van Groningen; Martijn W F van den Hoogen; Marcia M L Kho; Joke I Roodnat; Katya A L Mauff; Dave L Roelen; Madelon van Agteren; Carla C Baan; Dennis A Hesselink
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

9.  The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy.

Authors:  Marieke van der Zwan; Marian C Clahsen-Van Groningen; Joke I Roodnat; Anne P Bouvy; Casper L Slachmuylders; Willem Weimar; Carla C Baan; Dennis A Hesselink; Marcia M L Kho
Journal:  Ann Transplant       Date:  2018-08-17       Impact factor: 1.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.